Premier Alternatives

IMBiologics (KRX: 493280)

Suwon-si, South Korea · Founded 2020 · Publicly Held

IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. IMBiologics (KRX: 493280) is based in Suwon-si, South Korea and was founded in 2020. It is now publicly traded; this page covers its private-market history, where its last recorded valuation was $262 million (Mar 2026). It has raised $99.1 million.

Last price · $/share
—
Implied valuation
$261.7M
Total raised
$99.1M
Last round
—

IMBiologics (KRX: 493280) key facts

  • IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics.
  • IMBiologics (KRX: 493280)’s last known valuation is $261.7M (Mar 2026).
  • It has raised $99.1M; the latest was IPO ($35.4M) in Mar 2026.
  • Notable investors include KB Investment, Korea Development Bank, IMM Investment, Shinhan Venture Investment, Partners Investment — 22 tracked in total.
  • Status: Publicly Held.
Free account
More of IMBiologics (KRX: 493280) with a free account
  • ·The complete investor list: 22 names
  • ·Watch IMBiologics (KRX: 493280): the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

IMBiologics (KRX: 493280) funding rounds

No rounds on record

No funding rounds for IMBiologics (KRX: 493280) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

IMBiologics (KRX: 493280) valuation

IMBiologics (KRX: 493280) is now publicly traded; this page covers its private-market history, where its last recorded valuation was $262 million (Mar 2026). Secondary trades, fund marks and rounds below are the private-market record; the listed share price is not tracked here.

IMBiologics (KRX: 493280) investors

22 investors are on record for IMBiologics (KRX: 493280), including KB Investment, Korea Development Bank, IMM Investment and Shinhan Venture Investment. By type, the record holds 5 venture capital firms and 1 asset manager.

About IMBiologics (KRX: 493280)

IMBiologics Corp is a next-generation biopharmaceutical company developing antibody therapeutics. Its proprietary IM-OpDECon platform enables the design of differentiated biologics targeting autoimmune diseases and immuno-oncology. The group leverages diverse antibody modalities to tackle critical unmet medical needs beyond the reach of current therapies. Its business areas are Antibody Research & Development and Autoimmune Diseases Immuno-Oncology. The group's pipeline products are IMB-101/102, IMB-201, and IMB-402.

Sector
Healthcare
HQ
Suwon-si, South Korea
Founded
2020
Employees
25
Ownership
Publicly Held

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$261.7M

IMBiologics (KRX: 493280)’s last known valuation, Mar 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.